Development of a New Early Detection Test to Reduce Racial Disparities in Endometrial Cancer (EC) Death Rates
Primary Purpose
Endometrial Carcinoma
Status
Completed
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
Biospecimen Collection
Focus Group
Survey Administration
Sponsored by
About this trial
This is an interventional screening trial for Endometrial Carcinoma
Eligibility Criteria
Inclusion Criteria:
- AIM 1: Self-identified white women (WW) or African American women (AAW) (will record Hispanic ethnicity)
- AIM 2: Self-reported history of abnormal uterine bleeding (AUB) or post-menopausal bleeding (PMB)
Exclusion Criteria:
- AIM 1: Women who do not identify as WW or AAW
- AIM 1: Women who are unable to speak and read English
- AIM 2: Prior hysterectomy
- AIM 2: Prior pelvic radiation or are unwilling to comply with instructions
- AIM 2: Pregnant women
Sites / Locations
- Mayo Clinic in Florida
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Aim 1 (focus group)
Aim 2 (vaginal kit)
Arm Description
Participants attend a focus group over 2 hours about endometrial cancer including knowledge of abnormal uterine bleeding, post-menopausal bleeding, risk factors, sources of medical information, barriers to seeking gynecologic care, and acceptance of tampon self-collection for endometrial cancer detection.
Participants receive a tampon kit for collection of vaginal samples.
Outcomes
Primary Outcome Measures
Differences in views on endometrial cancer (EC) risk between African American and white women and whether the former would be willing to participate in tampon testing (Aim 1)
Survey data will be reported as frequencies and proportions to describe the sample. Survey data will also be used to aid in interpretation of the qualitative data as appropriate.
Total deoxyribonucleic acid (DNA) (Aim 2)
Endometrial DNA (Aim 2)
Detection of EC-specific methylation markers (Aim 2)
Will test samples for top EC-specific DNA methylation markers using methylation-specific polymerase chain reaction and provide descriptive statistics for all measurements (mean, median, standard deviation). Will assess the percentage of samples that yield > 500 ng amplifiable DNA, which suffices for methylation assays.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT04474184
Brief Title
Development of a New Early Detection Test to Reduce Racial Disparities in Endometrial Cancer (EC) Death Rates
Official Title
Development of a Novel Early Detection Test to Reduce Racial Disparities in Endometrial Cancer (EC) Mortality
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Completed
Study Start Date
February 1, 2020 (Actual)
Primary Completion Date
January 25, 2023 (Actual)
Study Completion Date
January 25, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Mayo Clinic
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
This phase I trial investigates the development of a new early detection test to reduce racial disparities in endometrial cancer death rates. DNA samples collected from a tampon may be able to be used to detect endometrial cancer. Studying information from focus groups and vaginal samples of African American and white women may help researchers develop a less invasive and painful test to detect endometrial cancer. The purpose of this trial is to perform a demonstration project of tampon self-collection, assess percentage of samples returned; total and endometrial derived DNA quantity and quality, preliminarily test previously validated DNA methylation markers that may discriminate endometrial cancer from normal endometrium in tampon specimens.
Detailed Description
PRIMARY OBJECTIVES:
I. To conduct focus groups to elicit perceptions and knowledge among African American women (AAW) and white women (WW) concerning abnormal uterine bleeding (AUB)/post-menopausal bleeding (PMB), endometrial cancer (EC) risk factors, barriers to seeking medical evaluation, sources of medical information and acceptance and feasibility of tampon self-collection for laboratory testing.
II. To perform a demonstration project of tampon self-collection from 25 AAW and 25 WW with AUB/PMB in Jacksonville.
OUTLINE:
AIM 1: Participants attend a focus group over 2 hours about endometrial cancer including knowledge of abnormal uterine bleeding, post-menopausal bleeding, risk factors, sources of medical information, barriers to seeking gynecologic care, and acceptance of tampon self-collection for endometrial cancer detection.
AIM 2: Participants receive a tampon kit for collection of vaginal samples.
After completion of study enrollment, participants may be followed up annually for 10 years.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Endometrial Carcinoma
7. Study Design
Primary Purpose
Screening
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
33 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Aim 1 (focus group)
Arm Type
Experimental
Arm Description
Participants attend a focus group over 2 hours about endometrial cancer including knowledge of abnormal uterine bleeding, post-menopausal bleeding, risk factors, sources of medical information, barriers to seeking gynecologic care, and acceptance of tampon self-collection for endometrial cancer detection.
Arm Title
Aim 2 (vaginal kit)
Arm Type
Experimental
Arm Description
Participants receive a tampon kit for collection of vaginal samples.
Intervention Type
Procedure
Intervention Name(s)
Biospecimen Collection
Intervention Description
Receive vaginal kit for biospecimen collection
Intervention Type
Behavioral
Intervention Name(s)
Focus Group
Intervention Description
Attend focus group
Intervention Type
Other
Intervention Name(s)
Survey Administration
Intervention Description
Ancillary studies
Primary Outcome Measure Information:
Title
Differences in views on endometrial cancer (EC) risk between African American and white women and whether the former would be willing to participate in tampon testing (Aim 1)
Description
Survey data will be reported as frequencies and proportions to describe the sample. Survey data will also be used to aid in interpretation of the qualitative data as appropriate.
Time Frame
Up to 12 months
Title
Total deoxyribonucleic acid (DNA) (Aim 2)
Time Frame
Up to 12 months
Title
Endometrial DNA (Aim 2)
Time Frame
Up to 12 months
Title
Detection of EC-specific methylation markers (Aim 2)
Description
Will test samples for top EC-specific DNA methylation markers using methylation-specific polymerase chain reaction and provide descriptive statistics for all measurements (mean, median, standard deviation). Will assess the percentage of samples that yield > 500 ng amplifiable DNA, which suffices for methylation assays.
Time Frame
Up to 12 months
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
AIM 1: Self-identified white women (WW) or African American women (AAW) (will record Hispanic ethnicity)
AIM 2: Self-reported history of abnormal uterine bleeding (AUB) or post-menopausal bleeding (PMB)
Exclusion Criteria:
AIM 1: Women who do not identify as WW or AAW
AIM 1: Women who are unable to speak and read English
AIM 2: Prior hysterectomy
AIM 2: Prior pelvic radiation or are unwilling to comply with instructions
AIM 2: Pregnant women
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mark E Sherman
Organizational Affiliation
Mayo Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Mayo Clinic in Florida
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32224-9980
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Development of a New Early Detection Test to Reduce Racial Disparities in Endometrial Cancer (EC) Death Rates
We'll reach out to this number within 24 hrs